South Africa’s Health Product Regulatory Authority (SAHPRA) has approved the use of the twice-yearly HIV prevention drug, lenacapavir. In a statement released on 27 October, the regulatory body said ...

South Africa has become the first African country to register lenacapavir, a groundbreaking six-monthly HIV prevention ...

The drug, Lenacapavir, is the world's first injectable Pre-Exposure Prophylaxis (PrEP). According to the World Health ...

South Africa has become the first African country, and our medicines regulator the third worldwide, to register the ...

The South African Health Products Regulatory Authority (SAHPRA) has announced the registration of lenacapavir, making South ...

HIV prevention drug Lenacapavir, which has been tested in South Africa during clinical trials, will be made available in the country in 2026 for high-risk groups.

South Africa has become the first African country — and our medicines regulator the third worldwide — to register the revolutionary twice-a-year anti-HIV jab, lenacapavir (LEN). The shot could bring ...

The South African Health Products Regulatory Authority has approved Lenacapavir, a long-acting injection that prevents HIV ...

Camber Pharmaceuticals’ parent company, Hetero, a global company specializing in active pharmaceutical ingredients and ...

KZN to receive Lenacapavir,new long-acting HIV prevention injection. Minister Motsoaledi confirms rollout to 360 clinics, for ...

Dr Joel Steingo of TB HIV Care says Lenacapavir could be a breakthrough in reducing infections, especially at a time when ...

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.